STANDARD BIOTOOLS INC. - 8-K Filing
Standard BioTools Inc. entered into a merger agreement on June 6, 2026, to combine with Treeline Biosciences in an all-stock transaction valued at $2.5 billion for Treeline and $460 million for Standard BioTools (subject to adjustments based on net cash). The deal is expected to close by the end of 2026 after shareholder approvals and regulatory clearances, resulting in former Treeline stockholders owning approximately 84% of the combined company. Additionally, Standard BioTools will divest its mass cytometry and microfluidics businesses. (Items: 1.01 Entry into a Material Definitive Agreement, 3.02 Unregistered Sales of Equity Securities, 5.01 Changes in Control of Registrant, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi)
Tickers: $LAB